Natural Alternative to Antibiotics

Brisbane, June 21, 2017 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).

Oral therapeutics for gastrointestinal disease in livestock and humans

- Natural, safe, non-antibiotic therapeutic that prevents and treats gastrointestinal diseases, including diarrhoea

- Meets the need to reduce the use of antibiotics and zinc oxide in animal production

- Unlike antibiotics and zinc oxide, Detach(TM) will not contribute to antimicrobial resistance (AMR)

Detach (TM) - Poised for swift market entry
Commercially validated, supported by demand

- A clear path to market: Launch in 2018
o Manufacturing complete at commercial scale and global supply confirmed

- Introduction of DetachTM is supported by industry, government, retailer & consumer demand

- Detach(TM) will be supplied in Australia via preexisting distribution channels (Australian pork industry is heavily consolidated)

- Focus now is on planning market launch

- Launch in Australia will provide leverage into Asia

- Global partnering interest for worldwide commercialisation

What Next?
Detach(TM) - A Pipeline in a Product

Other Detach(TM) presentations:
- Livestock: in-feed
- Livestock: in-water

Potential product extensions for the core components of Detach(TM)

Partnering Opportunities for:
- Human GI conditions (diarrhoea; inflammatory bowel disease; irritable bowel syndrome)

Anatara Investment Overview

- Experienced board and management team with proven track record

- Lead product, Detach(TM), has a clear route to market
o Commercially validated and proven efficacy
o Development strategy de-risked and revenues within 2 years

- Well funded - sufficient to launch Detach(TM) in key markets

- Product Pipeline - animal product leads to human product development for partnering opportunities

- Seasoned Operational Team
o Regulatory, Manufacturing, IP, Clinical Trials, R&D

To view the full presentation, please visit:

To view the video presentations, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.



General inquiries:
Dr Mel Bridges
Chairman & CEO
Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anataralifesciences.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 47) (Last 30 Days: 191) (Since Published: 4421) 

Anatara Lifesciences Ltd NEWS: RECENT VISITS (2564)

Research Report

Social Media